Benign Prostatic Hyperplasia News and Research

RSS

Sophiris announces data from PRX302 transrectal safety study on Benign Prostatic Hyperplasia

Sophiris Bio Inc. today announced data from its transrectal safety study, in which PRX302, the company's drug candidate for the treatment of Benign Prostatic Hyperplasia (BPH or enlarged prostate), was well tolerated through three months following a transrectal injection.

1 Sep 2012

Acorda’s GGF2 can improve erectile function after cavernous nerve damage

Acorda Therapeutics, Inc. announced data from a preclinical study showed that treatment with Glial Growth Factor 2 (GGF2) improved erectile function in an animal model following a cavernous nerve (CN) injury, a common complication of prostate surgery.

29 Aug 2012

Symptom relief at the core of prostate patient management

More focus should be placed on relieving the most bothersome or “core” symptom for patients with benign prostatic hyperplasia, report Korean researchers.

11 Jul 2012

AUA Foundation introduces It's Time to Talk About OAB campaign

On the heels of the fourth annual World Continence Week, the American Urological Association (AUA) Foundation has launched "It's Time to Talk About OAB," a nationwide education campaign designed to elevate awareness of Overactive Bladder (OAB), a common, yet often untreated condition, as a public health issue.

20 Jun 2012

Urologic conditions contribute to major economic burden in the U.S.

Urologic conditions like urinary tract infections, kidney stones, and prostate cancer are a major economic burden on Americans, resulting in health care costs of close to $40 billion annually, according to a newly released national report that charts the demographic and economic impact of urologic diseases in the U.S.

19 May 2012

New embolization procedure may bring hope to men with enlarged prostate

A new interventional radiology treatment, prostatic artery embolization, may bring hope to men with debilitating symptoms caused by an enlarged prostate, say the group of researchers who pioneered its use.

26 Mar 2012

Clear link between androgenetic alopecia and benign prostate hyperplasia

Spanish scientists have confirmed that there is a clear relationship between androgenetic alopecia (common premature baldness) and benign prostate hyperplasia (BPH), a benign enlargement of the prostate that appears in aging men and is associated with certain hormones as dihydrotestosterone. This condition appears in 50% of men over 60 year old and causes voiding syndrome i.e. urinary frequency.

16 Mar 2012

Endo fourth quarter total revenues increase 57% to $803.4 million

Endo Pharmaceuticals today reported financial results for the fourth quarter of 2011.

24 Feb 2012

KSU professor turns to nutrition to tackle prostate cancer

A Kansas State University professor is turning to nutrition to tackle prostate cancer. Brian Lindshield, assistant professor of human nutrition, is helping men make more informed diet decisions by studying foods and dietary supplements that may reduce the risk of prostate cancer. Prostate cancer is one of the most common forms of cancer among men in the United States.

24 Jan 2012

Saw Palmetto ineffective in patients with enlarged prostate: Study

A new study showed that much cited saw-palmetto supplements for the middle aged to cope with the symptoms of an enlarged prostate might not be working at all.

8 Jan 2012

PSA testing that combines blood test with other factors can help men avoid prostate biopsies

Prostate cancer screening that combines an adjusted blood test with other factors including the size of the gland, the patient's overall weight and family history, can help up to one-quarter of men avoid biopsies and the risks associated with them, a Beth Israel Deaconess Medical Center-led research team says.

12 Dec 2011

Treatment for acute urinary retention due to BPH varies among countries

Men who experience a sudden inability to pass urine because of a non-cancerous enlarged prostate are hospitalised and treated differently depending on where they live, according to an international study published online by the urology journal BJUI.

28 Nov 2011

Watson receives FDA approval for Androderm lower-dose formulations

Watson Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved its Androderm (testosterone transdermal system) 2 mg and 4 mg formulation.

21 Oct 2011

Selected prescription drugs contribute to 10% of lower urinary tract symptoms among men

Use of selected prescription medications, including antidepressants, antihistamines, bronchodilators, anticholinergics, sympathomimetics, and diuretics contribute to 10 percent of lower urinary tract symptoms among men according to a Kaiser Permanente study published in the Archives of Internal Medicine.

11 Oct 2011

More of saw palmetto does not reduce urinary symptoms related to BPH

Men with urinary problems related to an enlarged prostate who received increasing doses of the fruit extract saw palmetto did not experience a reduction in these symptoms compared to men who received placebo, according to a study in the September 28 issue of JAMA.

28 Sep 2011

Saw Palmetto ineffective in patients with enlarged prostate: Study

A new study showed that much cited saw-palmetto supplements for the middle aged to cope with the symptoms of an enlarged prostate might not do much at all.

28 Sep 2011

Impax confirms JALYN patent challenge

Impax Laboratories, Inc. today confirms that it has initiated a challenge of the patents listed in connection with JALYN capsules.

13 Sep 2011

Mylan introduces generic version of Uroxatral for benign prostatic hyperplasia

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has shipped Alfuzosin Hydrochloride Extended-release Tablets, 10 mg.

12 Aug 2011

Protox reports net loss of $3.2 million for second quarter 2011

Protox Therapeutics Inc., a developer of innovative products for the treatment of urological diseases, today announced financial results and achievements for the quarter ended June 30, 2011.

10 Aug 2011

New study supports DNA-based 'biomarker' blood test for prostate cancer screening

A new study supports the use of a DNA-based "biomarker" blood test as a complement to the prostate-specific antigen (PSA) test currently offered to screen men for prostate cancer. University of Cincinnati (UC) researchers report their findings online ahead of print in the British Journal of Cancer.

8 Aug 2011